ALNYAlnylam Pharmaceuticals, Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~21% a year FCF growth. The price demands less than its three-year revenue growth of 53% a year, expectations look modest.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ALNY's price assumes
Alnylam Pharmaceuticals, Inc. trades at 114× earnings against 19.8× for the median Biotechnology name, more expensive than its own group.
Trailing P/E · Biotechnology median 19.8 · 5.75× the median: the market pays up for this one
- Price / sales
- 14.7
Price / sales · as of 2025-Q4
- Free cash flow yield
- 1.6%
Free cash flow yield · Biotechnology median 4.3%
- Growth the price implies
- +21%
Growth the price implies · The price pays for +21% free cash flow growth a year for a decade; revenue has grown 53% a year over the last three.
Details›
- Price / bookas of 2025-Q4
- 69.2
- EV / EBITas of 2025-Q4
- 105
- EV / salesas of 2025-Q4
- 14.2
- Healthcare median P/E503 names
- 27.9
- Biotechnology median P/E242 names
- 19.8
- Free cash flow, trailing twelve months
- $465M
- Market capitalisation133.8 million shares, counted Jul 24, 2026
- $30.0B
- 3-year revenue growth
- +53%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.